Pharmaceutical Products Tenders & Contracts

Leidos Supply Ltd. intends to award a framework agreeement for the provision of Pfizer Solus Pharmaceutical Products for the UK Ministry of Defence. The agreement will be for the duration of 3 years. Team Leidos/MoD reserve the right to include additional Pfizer Solus products into the agreement that fall within the advertised CPV codes. The estimated 3-year value is £4,500,000.00 GBP.

Due to the impending implementation of the Lot 5 Molecular within the Southern Counties Pathology Molecular Diagnostics Service for Microbiology Services. There is the urgent requirement for the continuation of service whilst this transition takes place.

Medicines Supply Chain Partnership. 1 Year Extension via existing EofE framework, whilst new PPSA Framework is finalised

East Midlands Pharmacy Collaborative (EMPC) as the Authority wishes to establish a multi-supplier Framework Agreement on behalf of its member Trusts for the supply of Unlicensed Specials

The provision of Pharmaceutical Products

Purchase of Reagents

Project title: NHS National Framework for Tafamidis Offer reference number: CM/TNS/26/5750 Period of framework: 01 April 2027 to 31 May 2028 (14 months) with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Insulin pumps and consumables for diabetic patients

Supply of Dexcom G6/G7 monitors

Framework agreement for Licensed Wholesaler Services contract for the delivery of medicines to Trusts within the North East and North Cumbria, Yorkshire and The Humber and North West Regions. This was procured via an Open Procedure to award a Closed Framework.

In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.

Supply and Delivery Of Diphtheria, Tetanus And Pertussis (Acellular, Component) Vaccine (Adsorbed, Reduced Antigen(s) Content)

In accordance with the National Immunisation Advisory Committee Immunisation Guidelines of Ireland a National Contract for the Supply of Live Attenuated Influenza Vaccines (LAIV) to the HSE is required to vaccinate relevant cohorts and provide protection against Influenza. This contract will provide sufficient stock of LAIV to vaccinate relevant cohorts for the next 12 months. There is only one sole supplier of Live Attenuated Influenza Vaccines (LAIV) in Ireland.

This note formally records that the Transparency Notice was not published at the required stage of the process, due to a procedural oversight. Once identified, the issue was promptly escalated and corrective action was taken to ensure a notice is completed and published in line with the relevant regulatory and governance requirements. Internal processes and controls have since been reviewed to reduce the risk of this happening again. This medicine is a NICE approved product which is not currently available for procurement under the Bleeding Disorders Framework, managed by NHS England. In order for Welsh patients to obtain access to this medicine while a contract is being negotiated between the supplier and NHS England, this contract is being direct awarded to SOBI.

PROCUREMENT OF GIVINOSTAT 8.86MG/ML ORAL SUSPENSION SUGAR-FREE, 140 mL

PROCUREMENT OF AGALSIDASE ALFA 3.5MG/3.5ML CONCENTRATE FOR SOLUTION FOR INFUSION, 3.5 mL, vial, PACK OF 1 (HOMECARE)

Public Health Wales has a network of microbiology laboratories across Wales which provide diagnostic microbiology services to Health Boards as well as surveillance activities for the protection of Public Health. Sexual Health screening in Wales was rationalised in 2011 with testing provided from three sites: UHW / Imperial Park Unit 5 (IP5) in Newport, Ysbyty Glan Clwyd in Rhyl, and Singleton Hospital in Swansea. A Managed Service Contract (MSC) was put in place in 2013 and PHW plan to continue this regional approach and provide analysis of sexual health markers and related testing from the three sites with support and clinical input from Welsh Specialist Virology Centre, Cardiff. This contract is a short term contract for the supply of consumables for PHW owned equipment whilst a whilst a full procurement is conducted.